Novalgen Overview

  • Founded
  • 2018
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $7.92M
Latest Deal Amount
  • Investors
  • 1

Novalgen General Information


Developer of comprehensive immunotherapy platform designed to make biological medicines. The company's platform develops breakthrough therapies for cancer, inflammatory diseases and immune-related disorders through activating the T-Cell, enabling healthcare professionals to get advanced drugs for the treatment of cancer and related diseases.

Contact Information

Formerly Known As
Immunocare Limited
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Argyle House, Joel Street
  • Northwood Hills
  • London HA6 1NW
  • England, United Kingdom
+44 020 0000 0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novalgen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 31-May-2019 $7.92M 00.000 000.00 Completed Generating Revenue
To view Novalgen’s complete valuation and funding history, request access »

Novalgen Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Novalgen’s complete cap table history, request access »

Novalgen Executive Team (2)

Name Title Board Seat Contact Info
Nilesh Modi Chief Operating Officer & Board Member
Kerry Chester Chief Scientific Officer
To view Novalgen’s complete executive team members history, request access »

Novalgen Board Members (6)

Name Representing Role Since
Bharat Thakrar Novalgen Board Member 000 0000
Jitisha Nathwani Novalgen Board Member 000 0000
Nilesh Modi Novalgen Chief Operating Officer & Board Member 000 0000
Richard Fagen Novalgen Board Member 000 0000
Samit Hathi Novalgen Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Novalgen Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Convergys Capital Venture Capital Minority 000 0000 000000 0
To view Novalgen’s complete investors history, request access »